Checked

Retatrutide is not approved. Here is where it is on the road.

  1. Phase 2Published Aug 2023
  2. Phase 34 trials reported, Dec 2025 to Jul 2026
  3. SubmissionLilly plans Q1 2027. Not made yet.
  4. FDA reviewNo date exists
  5. ApprovalUnknown

ReachedPlanned, not doneNot started

Status as of 2026-11-19: retatrutide is investigational. FDA material says it has not been found safe and effective for any condition (FDA, content current as of 2026-10-01). Lilly said on 2026-07-23 that it plans to submit it to the FDA in the first quarter of 2027 (Lilly release, 2026-07-23). We found no report that a submission has been made. See the dated tracker.

What the phase 3 trials found

Mean weight change on the highest dose tested in each trial, shown next to that same trial's placebo group. Each trial enrolled different people for a different length of time, so read them one at a time, never against each other.

Efficacy estimand. Lilly toplines (2025-12-11, 2026-05-21, 2026-07-23); TRIUMPH-1 and TRIUMPH-4 also published in N Engl J Med (2026). Every arm, source and date

  • TRIUMPH-1obesity, 80 weeks
    12 mg−28.3%
    Placebo−2.2%
  • TRIUMPH-2type 2 diabetes, 80 weeks
    12 mg−20.8%
    Placebo−4.0%
  • TRIUMPH-3heart disease, 80 weeks
    12 mg−22.6%
    Placebo−3.2%
  • TRIUMPH-4knee osteoarthritis, 68 weeks
    12 mg−28.7%
    Placebo−2.1%

What retatrutide is

Retatrutide (Lilly development code LY3437943) is a once-weekly injectable drug that activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon. Medical journals call it an "investigational triple agonist" of those receptors (N Engl J Med, online 2026-09-29). "Investigational" means it is still being tested and has no approved use.

Lilly sponsors the large phase 3 program, called TRIUMPH for obesity and TRANSCEND-T2D for type 2 diabetes. Several results have been announced; two have been published in a peer-reviewed journal. See the trial evidence index for each study, its comparator, its source and its date.

How to read the numbers here

  • Every figure comes from a primary source and is shown with its date.
  • Results from different trials are never ranked against each other. Each trial enrolled different people, ran for a different length of time and used a different analysis.
  • A company "topline" release has not been through peer review. The trials index says which is which.
  • Nothing here is medical advice. See the editorial policy.

Start here

Contact us

Found an error, or have a question about a source? Email [email protected]. We cannot answer individual medical questions.

Last checked . Independent summary of published sources. Editorial policy and corrections